about
Gene doping: an overview and current implications for athletes.Neurobiological correlates in forensic assessment: a systematic reviewSystematic review of the mechanisms and evidence behind the hypocholesterolaemic effects of HPMC, pectin and chitosan in animal trials.Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.CD4 Count and HIV RNA Trends for HIV-Associated Lymphoproliferative Disorders in Malawi.Extranodal natural killer/T-cell lymphoma in Malawi: a report of three cases.Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi.Kaposi's sarcoma in Malawi: a continued problem for HIV-positive and HIV-negative individuals.Quantifying bias in survival estimates resulting from loss to follow-up among children with lymphoma in Malawi.Species-dependent binding of new synthesized bicalutamide analogues to albumin by optical biosensor analysis.Salvage chemotherapy for adults with relapsed or refractory lymphoma in MalawiRisk factors and reasons for treatment abandonment among children with lymphoma in Malawi.Successful Treatment of Classical Hodgkin Lymphoma During Pregnancy in Malawi.Translation, psychometric validation, and baseline results of the Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric measures to assess health-related quality of life of patients with pediatric lymphoma in MalawiApplying quality by design principles to the small-scale preparation of the bone-targeting therapeutic radiopharmaceutical rhenium-188-HEDPResponse to proposal for a novel cancer drug pricing modelAssessing Pharmaceutical Research and Development Costs
P50
Q34322797-9625D568-A725-47C4-8430-B60CC234F0EAQ34374306-89E3C7F4-BB64-419F-AE14-0EEB67F4096CQ35896192-06A95ACC-6B0A-4D3E-A7E8-59262FD51584Q38641699-1BD6321E-3A4C-416D-B267-8E9B17D653D9Q38761670-35657CAD-BDC7-4747-BAB7-88DD544B9E0DQ40055468-30916064-F37A-4CA1-BE87-5B93077F47CBQ40304324-85256B61-44FD-41EE-9374-2E0679543F3EQ40400561-206BAA32-1FA2-4498-A775-28A9515A9E32Q40451892-4A7F932B-C8BF-4629-9455-652724E028F4Q41222381-42B9B2B0-07DA-414D-BCE9-778C6D33F6C4Q41336820-6AB14845-FD1A-4705-AB9D-83F95EA0D1C7Q46608415-24AE1CED-CEA3-4459-B137-1C3156F5EC44Q46882564-B5A82BD7-1834-47D8-A7AF-2AC0071B82A4Q62489409-054613F6-21E5-415F-B9AC-0DFD78A41F07Q87090666-00323E48-2F5C-4073-8ADD-F15961151020Q89326525-243A78E1-C3D1-4941-999A-6EEA43F84900Q95512949-AE320409-E12A-44B2-B318-5A60A474338B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Toon van der Gronde
@ast
Toon van der Gronde
@en
Toon van der Gronde
@es
Toon van der Gronde
@nl
Toon van der Gronde
@sl
type
label
Toon van der Gronde
@ast
Toon van der Gronde
@en
Toon van der Gronde
@es
Toon van der Gronde
@nl
Toon van der Gronde
@sl
altLabel
AGMP van der Gronde
@en
prefLabel
Toon van der Gronde
@ast
Toon van der Gronde
@en
Toon van der Gronde
@es
Toon van der Gronde
@nl
Toon van der Gronde
@sl
P106
P1153
55551618600
P21
P31
P3835
toon-van-der-gronde2
P496
0000-0002-8688-8180
P569
2000-01-01T00:00:00Z